News

Deal Announcements

Chiasma Collects Series E Venture Funds

Monday, March 2, 2015 5:44:00 AM PDT | VentureDeal
   Jerusalem, Israel  --  Biopharma technology company Chiasma has garners $70 million in its fifth round of venture capital financing.

Chiasma is developing technologies to enable drugs to be administered into the bloodstream without the need for injections.

Investors in the round included Rock Springs Capital, Sofinnova Ventures, MPM Capital, 7 Med Health Ventures, Abingworth Management and ARCH Venture Partners.

The company will use the funds to build its sales and marketing capabilities.

Chiasma is preparing for the U.S. launch of its octreotide capsules for adults with acromegaly.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1